| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2024-07-26 |
| タイトル |
|
|
タイトル |
Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Hematologic response |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
JAK2 V617F allele burden |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Low-risk |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Polycythemia vera |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Ropeginterferon alfa-2b |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
metadata only access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_14cb |
| 著者 |
下田, 和哉
Qin, Albert
Komatsu, Norio
Kirito, Keita
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Polycythemia vera (PV) is a Philadelphia chromosome-negative myeloproliferative neoplasm characterized by clonal erythrocytosis. A phase 2 study reported that ropeginterferon alfa-2b is a well-tolerated and effective treatment for PV in Japanese patients. This post hoc analysis of the phase 2 data further evaluated outcomes in patients at low risk of thrombosis (low-risk PV). Among 20 patients with low-risk PV, 60.0% (12/20) and 85.0% (17/20) achieved < 45% hematocrit by weeks 24 and 52, respectively. The proportion of responders with complete hematologic response (CHR) was 60.0% (12/20) at week 52, and the median time to response was 11.9 months. The mean JAK2 V617F allele burden decreased from 75.8% at baseline to 53.7% at week 52. No patient experienced thrombosis or bleeding episodes. All patients experienced treatment-emergent adverse events (TEAEs) related to ropeginterferon alfa-2b, but no grade ≥ 3 TEAEs or deaths related to ropeginterferon alfa-2b occurred, and no new safety concerns arose. This analysis indicated that ropeginterferon alfa-2b may be an effective treatment option for Japanese patients with low-risk PV. |
|
言語 |
en |
| 内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Citation:Shimoda, K., Qin, A., Komatsu, N. et al. Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b. Int J Hematol (2024). https://doi.org/10.1007/s12185-024-03804-1 |
|
言語 |
en |
| 書誌情報 |
en : International Journal of Hematology
発行日 2024-07-01
|
| 出版者 |
|
|
出版者 |
Springer Science and Business Media LLC |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0925-5710 |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1865-3774 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1007/s12185-024-03804-1 |
| 権利 |
|
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
article (1.1 MB)
